带有放射性保护剂的可视化阴离子放射性微球:在TARE期间减少肝脏组织损伤和内/外科影像
Xun-Zheng Su1, En-Qi Qiao2,3,4,5, Wen-Yu Wu6
1State Key Laboratory of Digital Medical Engineering, Jiangsu Key Laboratory for Biomaterials and Devices, School of Biological Sciences & Medical Engineering, Southeast University, Nanjing, 210009, China.
Materials today. Bio
|February 12, 2026
概括
新的微球改善了肝癌的跨动脉放射栓塞 (TARE). 这些可视化,药物释放的珠子提供有针对性的放射治疗,同时保护健康的肝脏组织免受辐射损伤.
科学领域:
- 肝细胞癌 (HCC) 研究研究
- 放射治疗和干预性瘤学
- 生物材料和药物输送系统
背景情况:
- 超动脉放射栓塞 (TARE) 对于中期和晚期肝细胞癌 (HCC) 有效.
- 目前TARE的微球具有局限性,包括低于最佳的栓塞,非目标输送,不良的跟踪以及破坏正常组织的活性氧物种 (ROS) 生成.
- 需要改进的栓塞剂来增强TARE的疗效并最大限度地减少副作用.
研究的目的:
- 开发用于HCC治疗TARE的可可视化,阴离子,药物释放的新型微球.
- 为了使放射性同位素 (例如131I) 和放射性保护剂 (amifostine) 能够加载.
- 评估微球的栓塞性质,可视化,阿米福斯的加载/释放以及对正常肝组织的保护作用.
主要方法:
- 开发基于阴离子四级盐的微球.
- 用于放射治疗的131I和用于辐射保护的amifostine通过离子交换加载.
- 在体外和体内评估微球特性,包括栓塞,CT/DSA可视化,阿米福斯释放动力学和ROS中和.
- 对肝脏保护和TARE治疗疗效的评估.
主要成果:
- 开发的微球显示出良好的栓塞性质和通过CT和DSA持续可视性.
- 通过离子交换实现了有效的充电和局部释放的amifostine,中和ROS.
- 微球提供了向放射治疗,同时保护正常的肝脏组织,而不影响TARE疗效.
- 这种方法提高了阿米福斯的利用率,提高了放射治疗的精度.
结论:
- 新型可视化,释放药物的微球为TARE在HCC治疗中提供了有前途的进展.
- 这些微球通过将向放射治疗与局部辐射保护相结合来提高治疗精度.
- 开发的系统解决了当前TARE方法的关键局限性,提高了肝癌患者的安全性和有效性.
相关概念视频
03:18Radioactivity and Nuclear Equations
27.6K
Nuclear chemistry is the study of reactions that involve changes in nuclear structure. The nucleus of an atom is composed of protons and, except for hydrogen, neutrons. The number of protons in the nucleus is called the atomic number (Z) of the element, and the sum of the number of protons and the number of neutrons is the mass number (A). Atoms with the same atomic number but different mass numbers are isotopes of the same element.
A nuclide of an element has a specific number of protons and...
A nuclide of an element has a specific number of protons and...
27.6K
02:48Radioactive Decay and Radiometric Dating
37.4K
Radioactivity is a spontaneous disintegration of an unstable nuclide and is a random process, as all the nuclei in the sample do not decay simultaneously. The number of disintegrations per unit time is called the activity (A), which is directly proportional to the number of nuclei in the sample. The decay constant (λ) is an average probability of decay per nucleus in unit time.
37.4K
03:23Types of Radioactivity
19.8K
The most common types of radioactivity are α decay, β decay, γ decay, neutron emission, and electron capture.
Alpha (α) decay is the emission of an α particle from the nucleus. For example, polonium-210 undergoes α decay:
Alpha (α) decay is the emission of an α particle from the nucleus. For example, polonium-210 undergoes α decay:
19.8K
01:18Reducing Line Loss
393
In a three-phase circuit, line loss is an indicator of energy dissipated as heat due to the resistance of transmission lines. To address this, incorporating transformers into the system—a step-up transformer at the source and a step-down transformer at the load—is a strategic solution. Two three-phase transformers are introduced to improve this.
With a step-up transformer at the source, the voltage is increased, thereby reducing the current in the transmission lines since power loss in...
With a step-up transformer at the source, the voltage is increased, thereby reducing the current in the transmission lines since power loss in...
393
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
281
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
01:21Hepatic Portal System
6.3K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
6.3K